The problem regarding the influence that industry may exert on physicians through various types of payments is not of exclusively ethical nature, but has also important practical implications. Using money, industry may distort prescribing habits in favor of their own products, generally more costly, but not always more effective or better tolerated. Moreover, industry is interested in increasing the number of people to whom their products could be prescribed, thus widening the market. If physicians do not oppose these enticements, the patients and the citizens' tax funded National Health Service will pay the bill. In fact, any largesse from the Sales & Marketing divisions of pharmaceutical industries is paid, indirectly and via major financial returns related to an increase in prescriptions, by citizens. In USA this is now demonstrated with the analysis of the first data on transfers of money from industry to physicians made publicly available after the implementation of the Physician Payment Sunshine Act.
Il problema dell’influenza che l’industria può avere sui medici mediante pagamenti di vario tipo non è esclusivamente etico, bensì ha importanti implicazioni pratiche. Tramite il denaro, l’industria può distorcere le abitudini prescrittive a favore dei propri prodotti, generalmente più costosi e non sempre più sicuri, efficaci e tollerati. Inoltre, l’industria ha tutto l’interesse ad ampliare il numero di persone cui possono essere prescritti i propri farmaci, allargando così il mercato. Se i medici non si oppongono a queste lusinghe, a pagare sono i pazienti e il Sistema Sanitario Nazionale (SSN) fondato sulle tasse dei cittadini. Ogni elargizione proveniente dalle divisioni Sales & Marketing delle case farmaceutiche è pagata, indirettamente e tramite un ampio ritorno in termini di aumento di prescrizioni, dai cittadini. Negli USA questo è ora dimostrato dall’analisi dei primi dati relativi ai trasferimenti di denaro dall’industria ai medici resi pubblicamente disponibili dall’implementazione del Physician Payment Sunshine Act.
Chi paga le “liaisons dangereuses” tra medici e industria? = Who pays the "dangerous liaisons" between doctors and industry? / P. Vercellini. - In: RECENTI PROGRESSI IN MEDICINA. - ISSN 2038-1840. - 107:9(2016 Sep), pp. 459-462. [10.1701/2354.25220]
Chi paga le “liaisons dangereuses” tra medici e industria? = Who pays the "dangerous liaisons" between doctors and industry?
P. VercelliniPrimo
2016
Abstract
The problem regarding the influence that industry may exert on physicians through various types of payments is not of exclusively ethical nature, but has also important practical implications. Using money, industry may distort prescribing habits in favor of their own products, generally more costly, but not always more effective or better tolerated. Moreover, industry is interested in increasing the number of people to whom their products could be prescribed, thus widening the market. If physicians do not oppose these enticements, the patients and the citizens' tax funded National Health Service will pay the bill. In fact, any largesse from the Sales & Marketing divisions of pharmaceutical industries is paid, indirectly and via major financial returns related to an increase in prescriptions, by citizens. In USA this is now demonstrated with the analysis of the first data on transfers of money from industry to physicians made publicly available after the implementation of the Physician Payment Sunshine Act.File | Dimensione | Formato | |
---|---|---|---|
Vercellini_PostPrint_RecentiProgMed_2016.pdf
accesso riservato
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
66.72 kB
Formato
Adobe PDF
|
66.72 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
RecentiProgressiMedicina_2016.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
77.79 kB
Formato
Adobe PDF
|
77.79 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.